Effective treatments for atypical haemolytic uraemic syndrome (aHUS) have long been lacking, but the discovery that complement dysregulation is a major risk factor for this disease and the availability of the complement inhibitor eculizumab have improved the clinical picture. Legendre et al. have now published results from two prospective trials investigating eculizumab use in aHUS. Although we have come a long way, questions remain.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fremeaux-Bacchi, V. et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin. J. Am. Soc. Nephrol. 8, 554–562 (2013).
Le Quintrec, M. et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am. J.Transplant. 13, 663–675 (2013).
Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C. & Fremeaux-Bacchi, V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat. Rev. Nephrol. 8, 643–657 (2012).
Electronic Medicines Compendium. Soliris—Summary of Product Characteristics[online], (2012).
U. S. Food and Drug Administration. Highlights of Prescribing Information: Soliris[online], (2011).
Legendre, C. M. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169–2181 (2013).
Legendre, C. M. et al. Efficacy of eculizumab in atypical hemolytic uremic syndrome with or without prior transplant [MP 034]. Poster at the ERA-EDTA meeting, Istanbul, Turkey, May 18–21 2013.
US National Library of Medicine. ClinicalTrials.gov[online], (2012).
Acknowledgements
The authors are grateful to Dr Julien Zuber for helpful discussions in relation to this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Fadi Fakhouri and Véronique Frémeaux-Bacchi have received fees from Alexion Pharmaceuticals for invited lectures. They are also members of an expert board supported by Alexion Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Fakhouri, F., Frémeaux-Bacchi, V. Eculizumab for atypical haemolytic uraemic syndrome: what next?. Nat Rev Nephrol 9, 495–496 (2013). https://doi.org/10.1038/nrneph.2013.150
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.150
This article is cited by
-
The renaissance of complement therapeutics
Nature Reviews Nephrology (2018)
